Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

Zacks Investment Research • 9 hours ago

Viatris to buy pain therapy maker Pacira Biosciences for $1.65 billion

Viatris said on Thursday ‌it will buy Pacira Biosciences for $1.65 billion, adding the ​pain therapy maker's ​products to its portfolio.

Reuters • Oct 8, 2026

Why Pacira BioSciences Skyrocketed Today

Pacira BioSciences is being bought out by Viatrias. The deal values the company at $36.50 per share or about $1.65 billion.

The Motley Fool • Oct 8, 2026

PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira's public shareholders and whether Pacira's Board adequately protected shareholder interests in negotiating and approving the transaction. Are You a PCRX Shareholder?

PRNewsWire • Oct 8, 2026

PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash.Halper Sadeh encourages Pacira shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Pacira and its board of directors violated the.

Business Wire • Oct 8, 2026

Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly

Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.

Investors Business Daily • Oct 8, 2026

Viatris to Buy Pacira BioSciences for $1.65 Billion

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.

WSJ • Oct 8, 2026

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities Expected to Be Synergistic With Viatris' Fast-Acting Meloxicam Opportunity Deal Anticipated to Close By the End of 2026 and to Be Immediately Accretive to Viatris' Financial Guidance Metrics Transaction Consistent With Viatris' Disciplined and Balanced Capital Allocation Strategy and Preserves Financial Flexibility PITTSBURGH and BRISBANE, Calif. , Oct. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, today announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.

PRNewsWire • Oct 8, 2026

2 Stocks Drawing Bearish Options Activity Today

Options traders are taking a bearish stance on two stocks attracting unusual volume today: Pacira BioSciences Inc (NASDAQ:PCRX) and Ring Energy Inc (NYSEAMERICAN:REI).

Schaeffers Research • Oct 8, 2026

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, Inc. ("Pacira BioSciences" or the "Company") (NASDAQ: PCRX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Viatris Inc. (NASDAQ: VTRS) for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The investigation concerns whether the Pacira BioSciences Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

Newsfile Corp • Oct 8, 2026